Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
- Study Title
- Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
- Teva Identifier
- BDP-AR-101
- ClinicalTrials.gov Identifier
- NCT01537692
- Study Status
- Completed
- Trial Condition(s)
- Female, Maleergic Rhinitis
- Interventions
- Drug: BDP HFA Nasal Aerosol | Drug: BDP HFA Inhalation Aerosol (QVAR)
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 45 Years
- Trial Duration
- 03/01/2009 - 06/01/2009
- Phase
- Phase 1
